litlas
Log inCreate account

Dale N. Gerding

Active 1971–2024

140
Papers
43,009
Citations
95
h-index
136
i10-index

Citations

Citations per year for Dale N. Gerding1936: 1 citations1971: 2 citations1974: 2 citations1975: 2 citations1976: 3 citations1977: 1 citations1978: 8 citations1979: 6 citations1980: 4 citations1981: 5 citations1982: 9 citations1983: 1 citations1984: 9 citations1985: 5 citations1986: 7 citations1987: 8 citations1988: 6 citations1989: 15 citations1990: 24 citations1991: 21 citations1992: 28 citations1993: 44 citations1994: 53 citations1995: 41 citations1996: 29 citations1997: 36 citations1998: 79 citations1999: 55 citations2000: 56 citations2001: 80 citations2002: 64 citations2003: 79 citations2004: 111 citations2005: 106 citations2006: 180 citations2007: 235 citations2008: 297 citations2009: 332 citations2010: 373 citations2011: 480 citations2012: 456 citations2013: 472 citations2014: 416 citations2015: 431 citations2016: 376 citations2017: 366 citations2018: 320 citations2019: 1,218 citations2020: 1,032 citations2021: 856 citations2022: 619 citations2023: 447 citations2024: 695 citations2025: 260 citations2026: 1 citations1937–1970: no citations, so these years are not shown1972–1973: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,960 citing papers, 34.6% of this breakdownUnited Kingdom: 704 citing papers, 8.2% of this breakdownCanada: 480 citing papers, 5.6% of this breakdownChina: 355 citing papers, 4.2% of this breakdownFrance: 313 citing papers, 3.7% of this breakdownGermany: 283 citing papers, 3.3% of this breakdownAustralia: 280 citing papers, 3.3% of this breakdownNetherlands: 229 citing papers, 2.7% of this breakdownItaly: 226 citing papers, 2.6% of this breakdownSpain: 192 citing papers, 2.2% of this breakdownSwitzerland: 185 citing papers, 2.2% of this breakdownIndia: 143 citing papers, 1.7% of this breakdown
0%34.6%Other 25.7%

Institutions

Fields

  • Medicine71.4%
  • Biochemistry, Genetics and Molecular Biology10.7%
  • Immunology and Microbiology10.7%
  • Health Professions1.8%
  • Environmental Science1.2%
  • Agricultural and Biological Sciences1.1%
  • Other3.1%

Topics

  • Clostridium difficile and Clostridium perfringens research18.1%
  • Antibiotic Use and Resistance6%
  • Gut microbiota and health5.7%
  • Nosocomial Infections in ICU5.5%
  • Microscopic Colitis5.5%
  • Viral gastroenteritis research and epidemiology4.2%
  • Other55%

Coauthors

All papers

Open in search
  1. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

    Authors: L. Clifford McDonald, Dale N. Gerding, Stuart Johnson, Johan Bakken, Karen C. Carroll, Susan Coffin, Erik R. Dubberke, Kevin W. Garey, Carolyn V. Gould, Ciaran Kelly, Vivian G. Loo, Julia Shaklee Sammons, Thomas J. Sandora, Mark H. Wilcox - Clinical Infectious Diseases 2017 cited by 2,652

  2. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes

    Authors: Alice Guh, Yi Mu, Lisa G. Winston, Helen Johnston, Danyel Olson, Monica M. Farley, Lucy Wilson, Stacy Holzbauer, Erin C. Phipps, Ghinwa Dumyati, Zintars G. Beldavs, Marion Kainer, Maria Karlsson, Dale N. Gerding, L. Clifford McDonald - New England Journal of Medicine 2020 cited by 840

  3. Burden of Clostridium difficile Infection in the United States

    Authors: Fernanda C. Lessa, Yi Mu, Wendy Bamberg, Zintars G. Beldavs, Ghinwa Dumyati, John R. Dunn, Monica M. Farley, Stacy Holzbauer, James Meek, Erin C. Phipps, Lucy Wilson, Lisa G. Winston, Jessica Cohen, Brandi Limbago, Scott K. Fridkin, Dale N. Gerding, L. Clifford McDonald - New England Journal of Medicine 2015 cited by 2,605

  4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

    Authors: Mark H. Wilcox, Dale N. Gerding, Ian R. Poxton, Ciarán P. Kelly, Richard Nathan, Thomas Birch, Oliver A. Cornely, Galia Rahav, Emilio Bouza, Christine Lee, G. Jenkin, Werner Jensen, You-Sun Kim, Junichi Yoshida, Lori Gabryelski, Alison Pedley, Karen Eves, Robert Tipping, Dalya Güriş, Nicholas A. Kartsonis, Mary-Beth Dorr - New England Journal of Medicine 2017 cited by 850

  5. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship

    Authors: Timothy H. Dellit, Robert C. Owens, John E. McGowan, Dale N. Gerding, Robert A. Weinstein, John P. Burke, W. Charles Huskins, David L. Paterson, Neil O. Fishman, Christopher Carpenter, Patrick J. Brennan, Marianne Billeter, Thomas M. Hooton - Clinical Infectious Diseases 2006 cited by 3,368

  6. Emergence and global spread of epidemic healthcare-associated Clostridium difficile

    Authors: Miao He, Fábio Miyajima, Paul Roberts, Louise Ellison, Derek Pickard, Melissa J. Martin, Thomas R. Connor, Simon R. Harris, Derek Fairley, Kathleen B. Bamford, Stephanie d’Arc, John Brazier, Derek Brown, John Coia, Gill Douce, Dale N. Gerding, Heejung Kim, Tse Hsien Koh, Haru Kato, Mitsutoshi Senoh, Tom Louie, Stephen Michell, Emma Butt, Sharon J. Peacock, Nick M Brown, Tom Riley, G. Songer, Mark H. Wilcox, Munir Pirmohamed, Ed J. Kuijper, Peter M. Hawkey, Brendan W. Wren, Gordon Dougan, Julian Parkhill, Trevor D. Lawley - Nature Genetics 2012 cited by 740

  7. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

    Authors: Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken Blount, Sarah Mische, Adam Charles Harvey - BMC Infectious Diseases 2022 cited by 81

  8. Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection

    Authors: Dale N. Gerding, Thomas Meyer, Christine U. Lee, Stuart H. Cohen, Uma K. Murthy, André Poirier, Trevor Van Schooneveld, Darrell S. Pardi, António Ramos, Michelle Barron, Hongzi Chen, Stephen Villano - JAMA 2015 cited by 333

  9. A Mouse Model of Clostridium difficile–Associated Disease

    Authors: Xinhua Chen, Kianoosh Katchar, Jeffrey D. Goldsmith, N. Nanda Nanthakumar, Adam Cheknis, Dale N. Gerding, Ciarán P. Kelly - Gastroenterology 2008 cited by 525

  10. An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile

    Authors: L. Clifford McDonald, George Killgore, Angela Thompson, Robert C. Owens, Sophia V. Kazakova, Susan P. Sambol, Stuart Johnson, Dale N. Gerding - New England Journal of Medicine 2005 cited by 2,009

  11. Clostridium difficilebinary toxin CDT

    Authors: Dale N. Gerding, Stuart Johnson, Maja Rupnik, Klaus Aktories - Gut Microbes 2013 cited by 409

  12. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection

    Authors: Erik R. Dubberke, Christine H. Lee, Robert Orenstein, Sahil Khanna, Gail Hecht, Dale N. Gerding - Clinical Infectious Diseases 2018 cited by 140

  13. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials

    Authors: Stuart Johnson, Thomas Louie, Dale N. Gerding, Oliver A. Cornely, Scott Chasan-Taber, David Fitts, Steven P Gelone, Colin Broom, David M. Davidson, for the Polymer Alternative for CDI Treatment (PACT) investigators - Clinical Infectious Diseases 2014 cited by 523

  14. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

    Authors: Dale N. Gerding, Ciarán P. Kelly, Galia Rahav, Christine Lee, Erik R. Dubberke, Princy Kumar, Bruce Yacyshyn, Dina Kao, Karen Eves, Misoo C. Ellison, Mary E. Hanson, Dalya Güriş, Mary Beth Dorr - Clinical Infectious Diseases 2018 cited by 206

  15. Clostridium difficile infection: new developments in epidemiology and pathogenesis

    Authors: Maja Rupnik, Mark H. Wilcox, Dale N. Gerding - Nature Reviews Microbiology 2009 cited by 1,397

  16. Toxin B is essential for virulence of Clostridium difficile

    Authors: Dena Lyras, Jennifer R. O’Connor, Pauline M. Howarth, Susan P. Sambol, Glen P. Carter, Tongted Phumoonna, Rachael Poon, Vicki Adams, Gayatri Vedantam, Stuart Johnson, Dale N. Gerding, Julian I. Rood - Nature 2009 cited by 754

  17. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium

    Authors: Richard A. Stabler, Miao He, Lisa F. Dawson, Melissa J. Martin, Esmeralda Valiente, Craig Corton, Trevor D. Lawley, Mohammed Sebaihia, Michael A. Quail, Graham Rose, Dale N. Gerding, Maryse Gibert, Michel R. Popoff, Julian Parkhill, Gordon Dougan, Brendan W. Wren - Genome biology 2009 cited by 472

  18. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

    Authors: Stuart H. Cohen, Dale N. Gerding, Stuart Johnson, Ciarán P. Kelly, Vivian G. Loo, L. Clifford McDonald, Jacques Pepin, Mark H. Wilcox - Infection Control and Hospital Epidemiology 2010 cited by 2,943

  19. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections

    Authors: Glen P. Carter, Anjana Chakravorty, Tu Anh Pham Nguyen, Steven J. Mileto, Fernanda Schreiber, Lucy Li, Pauline M. Howarth, Simon Clare, Bliss A. Cunningham, Susan P. Sambol, Adam Cheknis, Iris Figueroa, Stuart Johnson, Dale N. Gerding, Julian I. Rood, Gordon Dougan, Trevor D. Lawley, Dena Lyras - mBio 2015 cited by 339

  20. Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

    Authors: Ellie J. C. Goldstein, Diane M. Citron, P.S. Sears, Farah Babakhani, Susan P. Sambol, Dale N. Gerding - Antimicrobial Agents and Chemotherapy 2011 cited by 109

  21. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

    Authors: Israel Lowy, Deborah C. Molrine, Brett Leav, Barbra M. Blair, Roger Baxter, Dale N. Gerding, Geoffrey Nichol, William D. Thomas, Mark D. Leney, Susan Sloan, Catherine A. Hay, Donna M. Ambrosino - New England Journal of Medicine 2010 cited by 745

  22. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update

    Authors: Larry K. Kociolek, Dale N. Gerding, Ruth Carrico, Philip C. Carling, Curtis J. Donskey, Ghinwa Dumyati, David T. Kuhar, Vivian G. Loo, Lisa L. Maragakis, Monika Pogorzelska‐Maziarz, Thomas J. Sandora, David J. Weber, Deborah S. Yokoe, Erik R. Dubberke - Infection Control and Hospital Epidemiology 2023 cited by 88

  23. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials

    Authors: Dale N. Gerding, Oliver A. Cornely, Simon Grill, Hilke Kracker, Anne Claire Marrast, Carl Erik Nord, George H. Talbot, Martha Buitrago, Iulian Diaconescu, Cláudia Murta de Oliveira, Liliana Preoțescu, John Pullman, Thomas Louie, Mark H. Wilcox - The Lancet Infectious Diseases 2019 cited by 65

  24. Clostridium Difficile-Associated Diarrhea and Colitis

    Authors: Dale N. Gerding, Stuart Johnson, Lance R. Peterson, Maury E. Mulligan, Joseph Silva - Infection Control and Hospital Epidemiology 1995 cited by 638